August 13, 2012
- Learn how the FDA bypassed or ignored safety issues on major drug approvals from Ronald Kavanagh, who was a drug reviewer for the FDA in the Center for Drug Evaluation and Research from 1998 to 2008
- He reveals some of the internal rules of the FDA that are clearly designed to thwart serious safety reviews from the get-go, and other loopholes frequently used by drug companies to circumvent safety investigations
- Five years ago, a Subcommittee on Science and Technology report entitled “FDA Science and Mission at Risk” detailed how the FDA cannot fulfill its mission, in part because its scientific base has eroded and its scientific organizational structure is weak
- The subcommittee concluded the FDA’s failures place the health of Americans and the financial health of the nation at grave risk
The following video features attorney, Stephen Kohn, executive director of the National Whistleblowers Center and attorney for the FDA whistleblowers in the recently revealed FDA spy operation against them2.
"For the first time, we now have a glimpse into what domestic surveillance of whistleblowers looks like in this country with the modern technological developments," Kohn says. "The agency [sought] to destroy the reputation of these whistleblowers forever."